Ladenburg Thalmann set a $57.00 target price on CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) in a report published on Monday. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Piper Jaffray Cos. reiterated an overweight rating and set a $21.00 price target on shares of CoLucid Pharmaceuticals in a research report on Friday, September 9th. Zacks Investment Research lowered CoLucid Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, June 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $30.45.

Shares of CoLucid Pharmaceuticals (NASDAQ:CLCD) opened at 31.06 on Monday. CoLucid Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $35.48. The firm’s market capitalization is $476.27 million. The firm has a 50-day moving average price of $15.26 and a 200-day moving average price of $9.18.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last announced its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.22. On average, equities analysts expect that CoLucid Pharmaceuticals will post ($3.91) earnings per share for the current fiscal year.

In other news, CEO Thomas P. Mathers sold 6,502 shares of the company’s stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $21.72, for a total value of $141,223.44. Following the completion of the sale, the chief executive officer now owns 256,916 shares in the company, valued at $5,580,215.52. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Thomas P. Mathers sold 6,000 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $23.32, for a total value of $139,920.00. Following the completion of the sale, the chief executive officer now owns 244,714 shares of the company’s stock, valued at approximately $5,706,730.48. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the stock. FMR LLC bought a new stake in shares of CoLucid Pharmaceuticals during the second quarter worth about $554,000. Vanguard Group Inc. raised its stake in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 900 shares during the period. Finally, Societe Generale bought a new stake in shares of CoLucid Pharmaceuticals during the second quarter worth about $464,000. Institutional investors and hedge funds own 36.92% of the company’s stock.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

5 Day Chart for NASDAQ:CLCD

Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.